NEW YORK, Feb. 10, 2014 (GLOBE NEWSWIRE) -- On January 30th Google, Inc. (Nasdaq: GOOG announced that its Board of Directors approved the distribution of Class C shares to its stockholders. NASDAQ OMX is providing the information below to clarify the effect of this distribution on Google Class A shares ...
As a result of this transaction, upon distribution the Google Class C shares will be added to all NASDAQ OMX Indexes that contain Google Class A shares, including, but not limited to, the NASDAQ-100 Index®, the NASDAQ Internet Index® and the NASDAQ OMX Global Index Family, effective prior to market open on the April 3, 2014, the ex-date of the distribution.
Both classes of shares will remain temporarily in the Indexes until the next quarterly rebalancing, when the Class A shares will be removed from the Indexes.
Prior to market open on Monday, June 23, 2014, Google Class A shares will be removed from the NASDAQ OMX Indexes and Google Class C shares will become the sole security representing Google in NASDAQ OMX Indexes.
New York, NY, March 11, 2014 – S&P Dow Jones Indices announces revised treatment of Google Inc. (NASD:GOOG) Class A and Class C in the S&P 500 and S&P 100 and related changes to methodology for the S&P 100, S&P 500, S&P MidCap 400, S&P Small Cap 600 and S&P TMI/CI indices:
Google is establishing a new class of capital stock and is paying a dividend of one share of this new class of capital stock for each outstanding share of Class A and Class B common stock.
Both Google Class A and Google Class C will be included in the S&P 500 and S&P 100 and there will not be a switch from Class A to Class C on June 20th as previously announced in a press release dated February 3, 2014.
3. What was the object of all this?
Page and Brin couldn't sell many of their Class B shares without losing the majority vote. But as the now
also have Class C shares they can sell all of those without a reduction in their vote.
1. I've sent an e-mail to Nasdaq IR requesting confirmation that GOOGL is still due to be delisted on June 23.
2. I've now established that of the letters historically added to a Nasdaq ticker (temporarily) the letter L signifies a status of 'Miscellaneous' - possibly a lucky break for smart money looking to exit GOOGL before retail catches on :-)
3. Your theory about approval following Breakthrough Therapy designation is still in play. The FDA's official reports confirm that only four new drugs have been granted BT status since the pathway was established, and that four new drugs have been approved via the BT pathway.
With this confirmation that BT status has been warranted by efficacy in study groups as small as 25 and 43 patients, it seems very likely that an antibiotic of interest to the inter-agency task force will be granted BT status on the basis of a 44-patient study - and subsequently approved.
The speculation as to whether or not GOOGL will be delisted by the Russell has now surely been trumped by the info you posted on the GOOG and GOOGL short interest.
Between April 15 and May 30 the GOOG short interest decreased from 2,806,301 to 2,729,337. Over that same period the GOOGL short interest increased from 2,958,259 to 3,949,632.
You would think an increase of 33.5% in one but not the other would have rung alarm bells with the retail holders of GOOGL.
The reason it hasn't is the same reason professional investors have the luxury yachts and retail investors are forever late to the party and feeding off scraps - retail investors BELIEVE the share price. They need share price movement to reassure them they're making the right decision in buying or selling.
Professional investors have always exploited that weakness, and are masters of the art of using the share price to make the tail wag the dog.
They've managed to sell an extra million shares of GOOGL in six weeks whilst manipulating share price movement to conceal their activities.
Retail investors will do nothing until the price starts to drop - and then still do nothing, because then they'll reason it's probably too late.
The info Pills posted further down this thread says it all.
Wanna make retail investors believe a $100 stock is a $10 stock? Easy - just use paid hacks to paint any good news as bad news, and sell enough shares at the key moments to nip any share price momentum in the bud.
Now that the safety of inhaled liposome delivery has been established, what the FDA and medical community see is the first safe aminoglycoside antibiotic - a far more suitable therapy for Tuberculosis than anything currently available.
But the analysts unite as one in pretending to be blissfully unaware of the TB angle. And share price movement completes the deception.
Retail investors believe the share price - allowing professional investors to take full advantage of a once in a lifetime opportunity.
1 and 2: The 'L' means Miscellaneous? Would imagine if the same thing had happened at Yahoo, tickers of YHOO and YHOOL would have made holders of the latter far more uneasy than seems to have been the case with GOOGL.
3: Your comparison of tute shares to tute numbers made me wonder if the high ownership could be linked to the theory of a secret ITFAR agenda. A search for 'Transave' (the predecessor company) and 'NIAID' unearthed a Fidelity Biosciences PR dated July 29 2009:
'Transave announced today that it has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Disease ... Transave and NIAID will collaborate on the planning, design and implementation of a clinical trial ...'
So this pending application for BT status is the latest development in an NIAID initiative conceived five years ago. And an institution with a current holding of around 15% was a major holder back then.
I wonder if Dennis Dixon and Ed Johnson have ever had lunch?
A current valuation of $10 a share would equate to the use of Aricace two years from now by fewer than 3,600 patients.
From a recent article on another biotech -
[ Noting that biotech acquisitions continue to rise, Benjamin says other companies in the industry that have been recently acquired, such as Santarius which Salix Pharmaceuticals (SLXP) bought in January 2014 for $2.6 billion, have been acquired at 6 to 10 times their 2014 projected revenues. Applying the low end of that valuation range, Benjamin says Spectrum's acquisition value is $1 billion. That's chump change for the large-cap pharmaceuticals that are shopping for companies that have promising new medical cures or treatments for cancer. On the stock's fundamentals, Benjamin applies an 8-times multiple to his projected 2015 revenues of about $188 million ...]
Applying Benjamin's "8-times multiple" to a price of $30,000 for a six-month course, and adding an uncertainty / delay discount of 25% per year -
$30,000 x 3,600 x 8 x 0.75 x 0.75 / 48,000,000 shares = $10.12
Now that the potential use in MDR-TB has finally been acknowledged, any valuation based upon expected sales must include off-label sales in TB.
Estimated target populations -
2,000,000,000 with latent TB *
12,000,000 with active TB *
630,000 with MDR-TB *
110,000 with NTM in US / Europe / Japan
? with NTM in Canada / Australia / New Zealand and other high-income countries
65,000 with CF in US / Europe
* 5% in high-income countries.
Aminoglycoside injections (this is a safer inhaled delivery) are right at the top of the WHO order of preference of antibiotics for MDR-TB.
TB is usually treated with a six-month course of relatively cheap pills, which nevertheless are sufficiently toxic to cause the treatment to fail in many cases through poor compliance - often resulting in MDR-TB.
Current valuation / equivalent users in 2016 -
$10 - 3,555
$15 - 5,333
$20 - 7,111
$30 - 10,666
$40 - 14,222
$50 - 17,777
This guidance suggests the millions of shares held by Russell tracker funds must be sold if GOOGL loses its Nasdaq listing -
Russell 3000® Growth Index Top 10 Holdings
Verizon Communications Inc
International Business Machines Corp
Google Class C, Inc
Philip Morris International Inc
All securities eligible for inclusion in Russell U.S. Indexes must trade on a major U.S. Exchange.
Bulletin board, pink sheet or over-the-counter (OTC) traded securities are not eligible for inclusion.
Annual Reconstitution (effective at the end of June) -
Stocks must be listed on the last trading day in May and Russell must have access to documentation on that date supporting the company's eligibility for index inclusion. This includes corporate description, verification of incorporation, number of shares outstanding and other information needed to determine eligibility.
If Russell has confirmed the completion of a corporate action, scheduled to become effective subsequent to a rebalance; the event may be implemented in conjunction with the rebalance to limit turnover, providing appropriate notice can be given.
I was wrong about Page and Brin now being able to sell all of their Class C shares without reducing their majority vote. Seems that WAS the reason for all this - but they were forced by a shareholder action into agreeing to sell a Class B share for every Class C share they sell.
Unless Google has applied for a NYSE listing (anybody?) it will be no easier to trade GOOGL after June 20 than is the case with a 'pink sheets' stock.
The GOOGL vote is effectively going to be worth zero for the foreseeable future. The considerably greater liquidity of GOOG will make this a no-brainer unless there's a factor of which I'm unaware.